News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
科濟藥業(02171.HK)CT0596和CT1190B研究結果摘要獲EHA年會以壁報展示
科濟藥業－Ｂ(02171.HK)公布，CT0596用於治療復發/難治性多發性骨髓瘤/漿細胞白血病的IIT研究結果摘要，及CT1190B用於治療復發/難治性B細胞非霍奇金淋巴瘤的IIT研究結果摘要，被2026年歐洲血液學協會「EHA」年會接受進行壁報展示。(de/d)~阿思達克財經新聞網址: www.aastocks.com
Reset
Send
The window will close in 5 seconds
科濟藥業(02171.HK)CT0596和CT1190B研究結果摘要獲EHA年會以壁報展示
Close
Recommend
2
Positive
2
Negative
3
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

科濟藥業－Ｂ(02171.HK)  -0.280 (-1.687%)    Short selling $16.64M; Ratio 17.923%   公布，CT0596用於治療復發/難治性多發性骨髓瘤/漿細胞白血病的IIT研究結果摘要，及CT1190B用於治療復發/難治性B細胞非霍奇金淋巴瘤的IIT研究結果摘要，被2026年歐洲血液學協會「EHA」年會接受進行壁報展示。(de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-05 16:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.